Free Trial
NASDAQ:ILMN

Illumina Q1 2025 Earnings Report

Illumina logo
$77.88 +1.37 (+1.79%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$77.97 +0.09 (+0.12%)
As of 05/2/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Illumina EPS Results

Actual EPS
N/A
Consensus EPS
$0.94
Beat/Miss
N/A
One Year Ago EPS
N/A

Illumina Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.03 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Illumina Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Illumina Earnings Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
See More Illumina Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Illumina? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Illumina and other key companies, straight to your email.

About Illumina

Illumina (NASDAQ:ILMN) offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

View Illumina Profile

More Earnings Resources from MarketBeat